Dr Eula Marie Crippen, PHD | |
41075 Bidarki Dr, Homer, AK 99603-9261 | |
(907) 617-6671 | |
(810) 255-4722 |
Full Name | Dr Eula Marie Crippen |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 41075 Bidarki Dr, Homer, Alaska |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255562666 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | PSY-PSY-LIC-4503 (Montana) | Secondary |
103TC0700X | Psychologist - Clinical | 106430 (Alaska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Eula Marie Crippen, PHD 41075 Bidarki Dr, Homer, AK 99603-9261 Ph: (907) 617-6671 | Dr Eula Marie Crippen, PHD 41075 Bidarki Dr, Homer, AK 99603-9261 Ph: (907) 617-6671 |
News Archive
Mylan Inc. today announced that it has launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg in France, Belgium, the UK, the Netherlands and Ireland.
VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.
The next generation of drugs will be designed on the basis of 3D protein models that scientists are creating. The Structural Genomics Consortium laboratory at Swedish medical university Karolinska Institutet has now made available the structure of PARP3, the four hundredth structure in this unique project to chart the body's proteins.
Researchers have found that the bacteria responsible for causing gangrene could also be used to treat patients with certain cancers.
› Verified 6 days ago